Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms anti-CD3/anti-CD19 T-cell engager (Inovio Pharmaceuticals), CD19-DBITE |
Target |
Action modulators, stimulants |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), CD3 stimulants(T cell surface glycoprotein CD3 stimulants) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| B-Cell Lymphoma | Preclinical | United States | 02 Apr 2019 |






